Cara

Shares of Cara Therapeutics Inc (NASDAQ: CARA) fell nearly 30 percent early Friday morning after the company released concerning top-line results from a phase 2B trial of its oral CR845 therapy for the treatment of pain associated with osteoarthritis of the hip or knee. But not all analysts are...